Glaukos Corporation has announced that it has completed its previously announced acquisition of Avedro, Inc.
‘Avedro will serve as the cornerstone of our new corneal health franchise,’ said Thomas Burns, Glaukos president and chief executive officer. ‘This transaction pairs two highly complementary, hybrid pharma and device organizations, combining Avedro’s novel bio-activated pharmaceutical solutions and R&D capabilities with Glaukos’ global commercial scale, proven market-building and shared reimbursement expertise, and extensive clinical and regulatory infrastructure. We’re excited to transform Glaukos into a global ophthalmic pharmaceutical and device leader capable of serving the vision care needs of physicians and their patients for years to come.
FURTHER INFORMATION
E: nsmith@glaukos.com
W: www.glaukos.com
